tiprankstipranks
Trending News
More News >
CanSino Biologics, Inc. Class H (HK:6185)
:6185

CanSino Biologics, Inc. Class H (6185) AI Stock Analysis

Compare
2 Followers

Top Page

HK

CanSino Biologics, Inc. Class H

(6185)

Rating:48Neutral
Price Target:
HK$34.00
▼(-1.73%Downside)
The most significant factor is the company's poor financial performance, which severely impacts the overall score. Technical analysis provides some positive signals, indicating potential for short-term gains. However, the unfavorable valuation due to negative earnings and lack of dividends further weighs down the score. Improving financial health is crucial for a better outlook.

CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)

CanSino Biologics, Inc. Class H Business Overview & Revenue Model

Company DescriptionCanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
How the Company Makes MoneyCanSino Biologics makes money primarily through the sale of its vaccine products to governments, healthcare organizations, and distributors. Revenue streams include direct sales of vaccines, partnerships with governments for vaccine distribution, and potentially licensing agreements for vaccine technologies. The company also engages in research collaborations and partnerships that may contribute to its revenue. In particular, the global demand for COVID-19 vaccines has been a significant factor in its recent earnings, with CanSino's COVID-19 vaccine being distributed in several countries.

CanSino Biologics, Inc. Class H Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
609.52M345.18M1.03B4.30B18.54M2.28M
Gross Profit
87.62M-876.02M-186.61M3.00B4.74M2.14M
EBIT
-272.44M-2.04B-1.37B1.91B-440.32M
EBITDA
698.90M-1.65B-1.03B1.98B-402.97M-204.90M
Net Income Common Stockholders
-1.48B-964.76M1.91B-358.49M-153.11M
Balance SheetCash, Cash Equivalents and Short-Term Investments
197.38M4.12B5.95B7.78B5.11B754.79M
Total Assets
0.009.32B11.47B11.87B6.75B1.78B
Total Debt
0.002.70B2.70B1.37B142.54M166.80M
Net Debt
197.38M653.34M-694.19M-4.08B-4.30B-35.65M
Total Liabilities
0.004.03B4.22B3.33B677.22M313.98M
Stockholders Equity
502.32M5.27B6.75B8.00B6.07B1.47B
Cash FlowFree Cash Flow
-1.53B-2.96B811.42M-740.16M-287.14M
Operating Cash Flow
-368.56M-916.25M-1.89B2.01B-469.39M-170.19M
Investing Cash Flow
-9.68M-449.65M-1.19B-2.53B-182.71M-797.77M
Financing Cash Flow
101.25M-7.58M854.60M1.56B4.94B1.09B

CanSino Biologics, Inc. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price34.60
Price Trends
50DMA
32.18
Positive
100DMA
32.40
Positive
200DMA
29.14
Positive
Market Momentum
MACD
0.52
Negative
RSI
57.10
Neutral
STOCH
81.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Positive. The current price of 34.6 is above the 20-day moving average (MA) of 33.13, above the 50-day MA of 32.18, and above the 200-day MA of 29.14, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 81.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6185.

CanSino Biologics, Inc. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
48
Neutral
HK$10.61B-4.41%94.98%85.69%
$10.37B42.636.14%1.32%
$7.42B6.959.19%5.60%
$6.17B18.5514.19%1.44%
$12.79B28.178.17%
59
Neutral
HK$3.76B21.094.47%-9.75%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6185
CanSino Biologics, Inc. Class H
34.60
12.80
58.72%
SBMFF
Sino Biopharmaceutical
0.58
0.21
56.76%
SHTDF
Sinopharm Group Co
2.18
-0.72
-24.83%
TRSBF
3SBio
2.22
1.42
177.50%
WXIBF
Wuxi Biologics (Cayman)
3.20
1.72
116.22%
HK:1873
Viva Biotech Holdings
1.78
1.14
178.13%

CanSino Biologics, Inc. Class H Corporate Events

CanSino Biologics Gains Approval for Inhaled TB Vaccine Trial in Indonesia
May 15, 2025

CanSino Biologics Inc. announced the approval of its Phase I clinical trial for an inhaled tuberculosis booster vaccine in Indonesia. This development is significant as it addresses the limitations of the existing Bacillus Calmette-Guerin vaccine by offering a booster that enhances mucosal immunity, potentially improving tuberculosis prevention efforts in high-burden regions.

CanSino Biologics Sets Agenda for 2024 AGM with Key Resolutions
May 13, 2025

CanSino Biologics Inc. has announced the agenda for its 2024 Annual General Meeting, scheduled for June 4, 2025, in Tianjin, China. The meeting will cover several key resolutions, including the approval of the 2024 financial reports, profit distribution plans, and reappointment of auditors. Additionally, shareholders will consider granting mandates for share issuance and repurchase, which could impact the company’s capital structure and market operations.

CanSino Biologics Reports Q1 2025 Financial Results with Increased Revenue
Apr 29, 2025

CanSino Biologics Inc. reported its unaudited financial results for the first quarter of 2025, showing a 20.02% increase in operating revenue compared to the same period last year. Despite the revenue growth, the company experienced a net loss attributable to shareholders, although significantly reduced from the previous year’s loss, indicating a potential improvement in financial health. The report highlights the company’s ongoing challenges in achieving profitability, yet suggests a positive trend in revenue generation.

CanSino Biologics to Review Q1 2025 Results in Upcoming Board Meeting
Apr 15, 2025

CanSino Biologics Inc. has announced an upcoming board meeting scheduled for April 29, 2025, where the board will review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and operational progress, potentially impacting its market positioning and stakeholder confidence.

CanSino Biologics Releases 2024 Annual Results
Mar 25, 2025

CanSino Biologics Inc. has announced its audited consolidated annual results for the year ending December 31, 2024. The results, which comply with the Hong Kong Stock Exchange’s listing requirements, have been reviewed and confirmed by the company’s board and audit committee. The annual report will be available to shareholders and on relevant websites, reflecting the company’s commitment to transparency and regulatory compliance.

CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration
Mar 12, 2025

CanSino Biologics Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend payment, reflecting the company’s financial performance and potential shareholder returns.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.